Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (3006)	10/4/2017 12:10:28 PM
From: tuck	Read Replies (1) \| Respond to of 3027

Re Mylan getting 20mg and 40mg before MNTA. Slept in a bit and missed the news and opportunity to bail for $15. This stock won't have a significant story for two or three years. Unless they can do better with Humira. But I expect at some point in the near future it will test prices seen in the premarket before the biosimilars generate excitement. Wondering if the Mylan approval is a sign of Gottlieb's influence; maybe it'll help biosimilars, too. Anyway, I'd revisit on said test. Hoping for a dead cat bounce tomorrow, but it may already have had it this morning. Company seems snakebit, to echo rkrw. I think, in a decade or so, I have a modest (~10%) profit on my current position. Cheers, Tuck